A recent review highlighted the emerging role of pharmacogenetic screening for the prevention of severe cutaneous adverse drug reactions (ADRs) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and hypersensitivity syndrome reaction (HSR).
It’s summertime, and given the scrutiny and strain the profession has been under these past several months, I suspect all of you are ready for a reprieve from the limelight.
A California lawsuit claims that manufacturers, distributors and sellers of fish oil supplements failed to give clear reasonable warnings that consumers are being exposed to unacceptably high levels of polychlorinated biphenyls, which are known carcinogens and teratogens.